Karen Spilizewski
InvestorManaging Director at RiverVest Venture Partners
Cleveland, Ohio
FoundedVentureMed Group
About
A biomedical engineer by training, Karen Spilizewski joined RiverVest in 2008 to manage the Cleveland office and was promoted to Managing Director in 2023, focusing on identifying and evaluating early-stage medical device technologies and supporting portfolio company CEOs. She previously directed medical device business development at BioEnterprise and spent 19 years at Avery Dennison, and holds an MBA, MS, and BS from Case Western Reserve University.
Experience
- RiverVest Venture PartnersManaging Directorcurrent2023 β present
- RiverVest Venture PartnersVice President2008 β 2023Cleveland, OH and St. Louis, MO
- Standard Bariatrics, IncMember Board Of Directors2018 β 2022Cincinnati, OH
- BioEnterpriseVice President, Business Development2005 β 2020Cleveland, OH
- Securus Medical GroupMember Board Of Directors2011 β 2018Cleveland, OH
- Neuros Medical, Inc.Board Observer2011 β 2017Willoughby Hills, OH
- Avery DennisonBusiness Development Manager1986 β 2005
Education
- Weatherhead School of Management at Case Western Reserve UniversityMaster of Business Administration (MBA)1989 β 1993
- Case Western Reserve UniversityMaster of Science (MS), Polymer Science1984 β 1986
- Case Western Reserve UniversityBachelor of Science (BS), Biomedical/Medical Engineering1980 β 1984
Skills & more
+12 more
CommercializationProduct DevelopmentR&DStart-upsLicensingMedical ImagingCorporate DevelopmentPrivate EquityISO 13485Business PlanningLifesciencesCross-functional Team LeadershipFrom Karen's professional profile.
Same school
Also attended Weatherhead School of Management at Case Western Reserve University25
+ 19 more
Also attended Case Western Reserve University41
+ 35 more
Shared employers
Also worked at RiverVest Venture Partners9
+ 3 more
Also worked at Standard Bariatrics, Inc2
Also worked at BioEnterprise3
Also worked at Neuros Medical, Inc.3
Deals Β· 1
VentureMed GroupBoard seat
via RiverVest Venture Partners Β· filed Feb 2025 Β· $7.5M raise
Attribution from SEC filings, press coverage, and firm rosters.























